Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:aims_to |
evaluate safety and efficacy
|
| gptkbp:business_model |
institutional review board
|
| gptkbp:completed |
gptkb:2019
|
| gptkbp:conducted |
multiple countries
patient consent good clinical practice guidelines |
| gptkbp:contributes_to |
clinical guidelines for heart failure
|
| gptkbp:focuses_on |
heart failure
|
| gptkbp:has_impact_on |
treatment protocols
|
| https://www.w3.org/2000/01/rdf-schema#label |
The DAPA-HF Trial
|
| gptkbp:includes |
randomized controlled trial design
|
| gptkbp:investigates |
gptkb:dapagliflozin
|
| gptkbp:involves |
patients with heart failure
multiple clinical sites |
| gptkbp:is_analyzed_in |
systematic reviews
adverse events long-term effects |
| gptkbp:is_associated_with |
improved patient outcomes
lower mortality rates |
| gptkbp:is_cited_in |
gptkb:guidelines
subsequent research studies |
| gptkbp:is_collaborative_with |
academic institutions
|
| gptkbp:is_compared_to |
dapagliflozin and placebo
|
| gptkbp:is_discussed_in |
scientific publications
medical conferences |
| gptkbp:is_documented_in |
clinical trial registries
|
| gptkbp:is_evaluated_by |
regulatory agencies
clinical assessments |
| gptkbp:is_funded_by |
gptkb:Astra_Zeneca
|
| gptkbp:is_influential_in |
pharmaceutical development
medical practice changes |
| gptkbp:is_led_by |
principal investigators
|
| gptkbp:is_linked_to |
improved heart function
|
| gptkbp:is_part_of |
global health initiatives
DAPA-HF program |
| gptkbp:is_recognized_as |
landmark study
|
| gptkbp:is_recognized_by |
medical community
|
| gptkbp:is_related_to |
SGLT2 inhibitors
|
| gptkbp:is_relevant_to |
diabetes management
cardiology field heart failure patients |
| gptkbp:is_reviewed_by |
peer reviewers
|
| gptkbp:is_significant_for |
heart failure treatment
|
| gptkbp:is_supported_by |
grants and funding
clinical research organizations clinical trial networks |
| gptkbp:is_utilized_by |
healthcare providers
|
| gptkbp:measures |
cardiovascular outcomes
|
| gptkbp:published_by |
peer-reviewed journals
medical journals |
| gptkbp:published_in |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:related_show |
improvement in quality of life
|
| gptkbp:reported_by |
gptkb:literature
health authorities |
| gptkbp:result |
gptkb:2020
|
| gptkbp:sponsored_by |
gptkb:Astra_Zeneca
|
| gptkbp:started_in |
gptkb:2017
|
| gptkbp:student_enrollment |
over 4,700 patients
|
| gptkbp:utilizes |
placebo-controlled methodology
|
| gptkbp:was_a_demonstration_of |
reduction in heart failure hospitalization
|
| gptkbp:bfsParent |
gptkb:The_New_England_Journal_of_Medicine
|
| gptkbp:bfsLayer |
6
|